Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement-19 K-51 K-121 K-5 0008 000-12 K-7 000Flux de trésorerie liés aux activités de financement16.13 M21.72 M-26 K7.41 M4 M23.64 M14.47 MFlux de trésorerie disponible-8.8 M-11.86 M-12.13 M-10.75 M-7.11 M-7.99 M-10.72 M
Phio Pharmaceuticals Corp. - Common Stock
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.